Bristol-Myers Squibb entered an exclusive global license and collaboration agreement with SystImmune for BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. BMS paid $800 million upfront with up to $500 million in contingent near-term payments and an additional $7.1 billion in development, regulatory, and sales milestones. SystImmune retained rights in Mainland China; BMS gained ex-China development and commercialization rights.
Key facts
AnnouncedDec 11, 2023
ClosedMar 01, 2024
Deal value$8.4B
Deal typeLicensing/Option
Therapeutic areaOncology
IndicationsNon-Small Cell Lung Cancer, Breast Cancer, Solid Tumors
Key assetsBL-B01D1 (EGFRxHER3 bispecific ADC)
MechanismEGFRxHER3 bispecific antibody-drug conjugate with topoisomerase I inhibitor payload